



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 7226995613/14/15 | +91 79 2646 8353, 4002 3839 | **Fax :** +91 79 26404961
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | **URL :** www.ishitadrugs.com

Date: 12th February, 2019

To,
The Company Section
The Bombay Stock Exchange
Phiroz Jijibhoy Towers
Dalal Street, Bombay- 400 001

Security Code: 524400

Dear Sir,

Sub: Outcome of Board Meeting held on 12th February, 2019 pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015.

This is to inform you that the Board of directors of the Company at its meeting held today on Tuesday, the 12th Day of February, 2019 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter ended on 31st December, 2018 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and oblige. Please do the needful.

Thanking You.

For, Ishita Drugs & Industries Ltd.

Authorised Signatory





PRATIK K KIKANI & ASSOCIATES

CHARTERED ACCOUNTANTS

MRN: 180309 FRN:145950W

PROPRIETOR: PRATIK KAUSHIKKUMAR KIKANI

PAN: ATVPK1876E

To,
The Board of Directors,
Ishita Drugs & Industries Ltd.
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LTD** for the period ended **31st December, 2018** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
PRATIK KAUSHIKKUMAR KIKANI
Chartered Accountants
Kikani Pratik
CA Pratik Kaushikkumar Kikani
Proprietor



PRATIK
KAUSHIKKU
MAR KIKANI

Digitally signed by
PRATIK
KAUSHIKKUMAR
KIKANI
Date: 2019.02.12
16:55:34 +05'30'

MRN: 180309
FRN: 145950W
UDIN: 19180309AAAAAB9800
Date: 12/02/2019
Place: Ahmedabad

Unaudited Financial Results for the Quarter Ended December 31, 2018

Amount in Lacs except Per Share data

| Particulars | Quarter Ended | | | Period Ended | | Year Ended |
|---|----------------|----------------|----------------|----------------|----------------|-----------------|
| | 3 Months Ended | 3 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 12 Months Ended |
| | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| | 31-Dec-18 | 30-Sep-18 | 31-Dec-17 | 31-Dec-18 | 31-Dec-17 | 31-Mar-18 |
| 1 INCOME | | | | | | |
| Revenue from Operations | 232.44 | 202.66 | 114.41 | 613.32 | 450.17 | 689.98 |
| Other Income | 0.48 | 2.24 | 3.96 | 4.11 | 6.12 | 11.93 |
| Total Income | 232.924 | 204.90 | 118.37 | 617.434 | 456.29 | 701.91 |
| 2 EXPENSES | | | | | | |
| (a) Cost of Material Consumed | 154.10 | 138.74 | 90.23 | 405.26 | 285.20 | 476.74 |
| (b) Purchase of Stock-In-Trade | 0.00 | 0.00 | 3.64 | 0.00 | 12.93 | 9.23 |
| (c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade | 5.01 | -2.12 | -25.51 | 5.89 | -11.56 | (12.71) |
| (d) Employee Benefit Expense | 24.82 | 22.31 | 20.06 | 67.20 | 59.93 | 79.99 |
| (e) Finance Cost | 0.64 | 0.38 | 0.82 | 2.21 | 2.31 | 11.26 |
| (f) Depreciation, Depletion and Amortisation Expense | 4.66 | 3.91 | 3.50 | 11.97 | 10.50 | 13.61 |
| (g) Other Expense | 32.75 | 31.05 | 18.80 | 93.17 | 76.40 | 90.76 |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| Total Other Expenses | 32.751 | 31.05 | 18.80 | 93.171 | 76.40 | 90.76 |
| Total Expenses | 221.99 | 194.27 | 111.54 | 585.69 | 435.71 | 668.88 |
| 3 Total Profit before Exceptional Items and Tax | 10.94 | 10.63 | 6.83 | 31.746 | 20.58 | 33.03 |
| 4 Exceptional Items | 0 | 0.00 | 0.00 | 0 | 0 | 0 |
| 5 Total Profit before Tax | 10.94 | 10.63 | 6.83 | 31.746 | 20.58 | 33.03 |
| 6 Tax Expense | | | | | | |
| 7 Current Tax | 3.36 | 2.31 | 0.90 | 7.96 | 4.50 | 8.71 |
| 8 Deferred Tax | 0.00 | 0.00 | 0.00 | 0 | 0 | (0.46) |
| 9 Total Tax Expenses | 3.36 | 2.31 | 0.90 | 7.96 | 4.50 | 8.25 |
| 10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 | 0.00 | 0 | 0 | 0 |
| 11 Net Profit Loss for the period from continuing operations | 7.58 | 8.32 | 5.93 | 23.79 | 16.08 | 24.78 |
| 12 Profit / (Loss) from discontinued operations before tax | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0 |
| 13 Tax Expenses of discontinued operations | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0 |
| 14 Net Profit / (Loss) from discontinued operations after tax | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0 |
| 15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0 |
| 16 Total Profit / (Loss) for the period | 7.58 | 8.32 | 5.93 | 23.79 | 16.08 | 24.78 |
| 17 Other Comprehensive Income net of Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| 18 Total Comprehensive Income for the Period | 7.58 | 8.32 | 5.93 | 23.79 | 16.08 | 24.78 |
| 19 Total profit or loss attributable to | | | | | | |
| Profit or loss, attributable to owners of parents | 0 | 0.00 | 0.00 | 0 | 0 | 0 |
| Total Profit or loss, attributable to non-controlling interests | 0 | 0.00 | 0.00 | 0 | 0 | 0 |
| 20 Total comprehensive income for the period attributable to | | | | | | |
| Comprehensive Income for the period attributable to the owners of parents | 0 | 0.00 | 0.00 | 0 | 0 | 0 |



| | | | | | | | |
|-------|--|--------|--------|--------|--------|--------|--------|
| | Total comprehensive income for the period attributable to the owners of parent non-controlling interests | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | Details of Equity Share Capital | | | | | | |
| | Paid-Up Equity Share Capital | 299.03 | 299.03 | 299.03 | 299.03 | 299.03 | 299.03 |
| | Face Value of Equity Share Capital | 10 | 10 | 10 | 10 | 10 | 10 |
| 22 | Details of Debt Securities | | | | | | |
| | Paid-Up Debt Capital | 0 | 0 | 0 | 0 | 0 | 0 |
| | Face Value of Debt Securities | 0 | 0 | 0 | 0 | 0 | 0 |
| 23 | Reserves Excluding Revaluation Reserves | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | Debenture Redemption Reserve | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | Earnings Per Share | | | | | | |
| (i) | Earnings Per Share for continuing operations | | | | | | |
| | Basic Earnings / (Loss) per share from continuing operations | 0.26 | 0.28 | 0.20 | 0.80 | 0.54 | 0.83 |
| | Diluted Earnings / (Loss) per share from continuing operations | 0.26 | 0.28 | 0.20 | 0.80 | 0.54 | 0.83 |
| (ii) | Earnings Per Share for discontinued operations | | | | | | |
| | Basic Earnings / (Loss) per share from discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 |
| | Diluted Earnings / (Loss) per share from discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 |
| (iii) | Earnings per Equity Share | | | | | | |
| | Basic Earnings / (Loss) per share from continuing and discontinued operations | 0.26 | 0.28 | 0.20 | 0.80 | 0.54 | 0.83 |
| | Diluted Earnings / (Loss) per share from continuing and discontinued operations | 0.26 | 0.28 | 0.20 | 0.80 | 0.54 | 0.83 |
| 26 | Debt Equity Ratio* | 0 | | 0 | 0 | 0 | 0 |
| 27 | Debt Service Coverage Ratio* | 0 | | 0 | 0 | 0 | 0 |
| 28 | Interest Service Coverage Ratio* | 0 | | 0 | 0 | 0 | 0 |
| | * The Company has no long term debt as on date | | | | | | |

The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of Net Profit after tax as previously reported under Indian GAAP and IndAS for the quarter ended 31st December, 2018 is as follows:

| Description | Quarter ended | Period Ended |
|--|---------------|--------------|
| | 31-Dec-18 | 31-Dec-18 |
| | Unaudited | Unaudited |
| Net Profit as per Previous Indian GAAP | 0.49 | 0.77 |
| Net Profit as per IndAS | 0.49 | 0.77 |

- NOTES**
- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 12, 2019.
 - The Limited Review of the results has been completed by the Statutory Auditors of the Company.
 - As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
 - The financial results for the quarter ended 31st December, 2018 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
 - Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
 - Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL
MANAGING DIRECTOR
DIN: 01031687

Place Ahmedabad
Date 12-Feb-19